Direct oral anticoagulant: Looking beyond convenience
Since the 2010 Food and Drug Administration approval of Dabigatran as the first non-vitamin-K antagonist oral anticoagulants or direct oral anticoagulants (DOACs) as it is now more commonly referred to, there has been much development in the field with increasing availability of different DOACs and...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Academy of Medicine Singapore
2024-02-01
|
| Series: | Annals, Academy of Medicine, Singapore |
| Online Access: | https://annals.edu.sg/direct-oral-anticoagulant-looking-beyond-convenience/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850283057122115584 |
|---|---|
| author | Samuel Ji Quan Koh Jonathan Jiunn Liang Yap |
| author_facet | Samuel Ji Quan Koh Jonathan Jiunn Liang Yap |
| author_sort | Samuel Ji Quan Koh |
| collection | DOAJ |
| description |
Since the 2010 Food and Drug Administration approval of Dabigatran as the first non-vitamin-K antagonist oral anticoagulants or direct oral anticoagulants (DOACs) as it is now more commonly referred to, there has been much development in the field with increasing availability of different DOACs and an expansion in indications of use. In the prevention of thromboembolism in nonvalvular atrial fibrillation (NVAF), DOACs have overtaken warfarin, which has been first-line therapy since the 1950s. In the most recent 2023 guidelines by the American Heart Association (AHA) for the diagnosis and management of atrial fibrillation, there is a Class 1A recommendation for patients who are candidates for anticoagulation without mechanical heart valve or history of moderate-to-severe rheumatic mitral stenosis to be prescribed DOACs over warfarin to reduce the risk of mortality, stroke, systemic embolism and intracranial haemorrhage.1 This stance is also echoed by the European Society of Cardiology guidelines in 2020,2 and—closer to home—in the Asia Pacific Heart Rhythm Society 2017 Consensus.3 |
| format | Article |
| id | doaj-art-a8f122a5480345b4a74fc255d8990edf |
| institution | OA Journals |
| issn | 2972-4066 |
| language | English |
| publishDate | 2024-02-01 |
| publisher | Academy of Medicine Singapore |
| record_format | Article |
| series | Annals, Academy of Medicine, Singapore |
| spelling | doaj-art-a8f122a5480345b4a74fc255d8990edf2025-08-20T01:47:51ZengAcademy of Medicine SingaporeAnnals, Academy of Medicine, Singapore2972-40662024-02-01532656610.47102/annals-acadmedsg.202413Direct oral anticoagulant: Looking beyond convenienceSamuel Ji Quan KohJonathan Jiunn Liang Yap Since the 2010 Food and Drug Administration approval of Dabigatran as the first non-vitamin-K antagonist oral anticoagulants or direct oral anticoagulants (DOACs) as it is now more commonly referred to, there has been much development in the field with increasing availability of different DOACs and an expansion in indications of use. In the prevention of thromboembolism in nonvalvular atrial fibrillation (NVAF), DOACs have overtaken warfarin, which has been first-line therapy since the 1950s. In the most recent 2023 guidelines by the American Heart Association (AHA) for the diagnosis and management of atrial fibrillation, there is a Class 1A recommendation for patients who are candidates for anticoagulation without mechanical heart valve or history of moderate-to-severe rheumatic mitral stenosis to be prescribed DOACs over warfarin to reduce the risk of mortality, stroke, systemic embolism and intracranial haemorrhage.1 This stance is also echoed by the European Society of Cardiology guidelines in 2020,2 and—closer to home—in the Asia Pacific Heart Rhythm Society 2017 Consensus.3https://annals.edu.sg/direct-oral-anticoagulant-looking-beyond-convenience/ |
| spellingShingle | Samuel Ji Quan Koh Jonathan Jiunn Liang Yap Direct oral anticoagulant: Looking beyond convenience Annals, Academy of Medicine, Singapore |
| title | Direct oral anticoagulant: Looking beyond convenience |
| title_full | Direct oral anticoagulant: Looking beyond convenience |
| title_fullStr | Direct oral anticoagulant: Looking beyond convenience |
| title_full_unstemmed | Direct oral anticoagulant: Looking beyond convenience |
| title_short | Direct oral anticoagulant: Looking beyond convenience |
| title_sort | direct oral anticoagulant looking beyond convenience |
| url | https://annals.edu.sg/direct-oral-anticoagulant-looking-beyond-convenience/ |
| work_keys_str_mv | AT samueljiquankoh directoralanticoagulantlookingbeyondconvenience AT jonathanjiunnliangyap directoralanticoagulantlookingbeyondconvenience |